• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钆塞酸增强 MRI 扫描后肝靶向放射治疗对正常肝实质信号强度变化的特征描述和预测。

Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.

机构信息

From the Departments of Radiation Oncology (A.D.N., K.K.S., T.W., M.B.), Pathology (F.K., S.C.W.), Radiology (C.K.K., B.T.), and Biostatistics (E.M.), Icahn School of Medicine at Mount Sinai, 1184 5th Ave, 1st Floor, Box 1236, New York, NY 10029-6574.

出版信息

Radiol Imaging Cancer. 2022 Jul;4(4):e210100. doi: 10.1148/rycan.210100.

DOI:10.1148/rycan.210100
PMID:35904411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9358658/
Abstract

Purpose To better characterize and understand the significance of focal liver reaction (FLR) development in a large cohort of patients who underwent gadoxetic acid-enhanced MRI after being treated with radiation therapy (RT) for hepatobiliary tumors. Materials and Methods This retrospective study evaluated 100 patients (median age, 65 years [first and third quartiles, 60-69 years]; 80 men) who underwent RT for hepatocellular carcinoma, bile duct tumors, or liver metastases at Mount Sinai Hospital between March 1, 2018, and February 29, 2020. CT simulation scans were fused to MRI scans obtained 1-6 months and 6-12 months after RT, using the hepatobiliary phase of the MRI. To define FLR volume, two radiation oncologists independently delineated the borders of the hypointensity observed on MRI scans in the liver region where RT was delivered. Biologically effective dose (BED) thresholds for the formation of FLRs were calculated, along with albumin-bilirubin (ALBI) scores and grades, and overall survival. Results Most patients developed FLRs, which decreased in volume over time. Median BED threshold values for FLR development were 63.6 Gy at 1-6 months and 88.7 Gy at 6-12 months. While higher baseline ALBI scores were associated with a lower rate of FLRs, there was a significant association between FLR volume and increase in ALBI score at 1-6 months ( = .048). Twelve- and 24-month survival estimates for the cohort were 81% and 48%, respectively. Histopathologic analysis of seven explanted liver specimens demonstrated findings consistent with radiation-induced liver disease. Conclusion FLRs were a clear measure of liver damage after RT and were associated with the development of liver dysfunction and focal radiation-induced liver disease. MRI, Radiation Therapy © RSNA, 2022.

摘要

目的

更好地描述和理解在接受肝胆肿瘤放射治疗(RT)后行钆塞酸增强 MRI 的大量患者中局灶性肝脏反应(FLR)发展的意义。

材料与方法

本回顾性研究纳入 2018 年 3 月 1 日至 2020 年 2 月 29 日期间在西奈山医院因肝细胞癌、胆管肿瘤或肝转移接受 RT 的 100 例患者(中位年龄,65 岁[第一和第三四分位数,60-69 岁];80 例男性)。CT 模拟扫描与 RT 后 1-6 个月和 6-12 个月的 MRI 扫描融合,使用 MRI 的肝胆期。为了定义 FLR 体积,两位放射肿瘤学家独立描绘了在接受 RT 的肝脏区域中 MRI 扫描上观察到的低信号的边界。计算了形成 FLR 的生物学有效剂量(BED)阈值,以及白蛋白-胆红素(ALBI)评分和等级以及总生存率。

结果

大多数患者出现了 FLR,其体积随时间减少。FLR 发展的中位 BED 阈值分别为 1-6 个月时 63.6 Gy 和 6-12 个月时 88.7 Gy。虽然较高的基线 ALBI 评分与较低的 FLR 发生率相关,但在 1-6 个月时,FLR 体积与 ALBI 评分增加之间存在显著关联( =.048)。该队列的 12 个月和 24 个月生存率估计分别为 81%和 48%。对 7 个切除的肝标本的组织病理学分析显示了与放射诱导的肝病一致的发现。

结论

FLR 是 RT 后肝脏损伤的明确指标,与肝功能障碍和局灶性放射性肝疾病的发展相关。

MRI,放射治疗

© RSNA,2022

相似文献

1
Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.钆塞酸增强 MRI 扫描后肝靶向放射治疗对正常肝实质信号强度变化的特征描述和预测。
Radiol Imaging Cancer. 2022 Jul;4(4):e210100. doi: 10.1148/rycan.210100.
2
Radiation-induced Liver Injury after 3D-conformal Radiotherapy for Hepatocellular Carcinoma: Quantitative Assessment Using Gd-EOB-DTPA-enhanced MRI.肝细胞癌三维适形放疗后放射性肝损伤:使用钆塞酸二钠增强MRI的定量评估
Acta Med Okayama. 2017 Feb;71(1):25-29. doi: 10.18926/AMO/54822.
3
Potential of Gd-EOB-DTPA as an imaging biomarker for liver injury estimation after radiation therapy.钆塞酸二钠(Gd-EOB-DTPA)作为放射治疗后肝损伤评估的影像学生物标志物的潜力。
Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):354-359. doi: 10.1016/j.hbpd.2019.05.005. Epub 2019 May 20.
4
Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA.立体定向消融体放射治疗小肝癌后局灶性肝反应的阈值剂量取决于肝功能:钆塞酸二钠增强磁共振成像的评估。
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):306-11. doi: 10.1016/j.ijrobp.2013.10.045.
5
Evaluation of Focal Liver Reaction after Proton Beam Therapy for Hepatocellular Carcinoma Examined Using Gd-EOB-DTPA Enhanced Hepatic Magnetic Resonance Imaging.使用钆塞酸二钠增强肝脏磁共振成像评估质子束治疗肝细胞癌后的肝脏局灶性反应
PLoS One. 2016 Dec 1;11(12):e0167155. doi: 10.1371/journal.pone.0167155. eCollection 2016.
6
Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS.探讨慢性肝病和肝硬化患者从钆塞酸增强 MRI 获得的功能肝脏成像评分(FLIS)的疗效:ALBI 分级与 FLIS 的关系。
Abdom Radiol (NY). 2022 Jul;47(7):2325-2334. doi: 10.1007/s00261-022-03557-7. Epub 2022 Jun 7.
7
Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system.使用钆乙氧基苄基二乙三胺五乙酸增强磁共振成像的肝胆期图像作为白蛋白-胆红素分级系统的成像替代指标。
Eur J Radiol. 2016 Dec;85(12):2206-2210. doi: 10.1016/j.ejrad.2016.10.010. Epub 2016 Oct 13.
8
Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.钆塞酸增强 MRI 中肝脏增强与肝功能的相关性:来自 SORAMIC 试验的肝细胞癌患者的多中心多供应商分析。
Eur Radiol. 2022 Feb;32(2):1320-1329. doi: 10.1007/s00330-021-08218-9. Epub 2021 Aug 31.
9
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.钆塞酸 MRI 和扩散加权成像在诊断肝细胞癌早期复发中的性能。
Eur Radiol. 2020 Jan;30(1):186-194. doi: 10.1007/s00330-019-06351-0. Epub 2019 Aug 1.
10
Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.钆塞酸增强肝胆期 MRI 和高 b 值扩散加权成像在慢性肝病患者中鉴别高分化肝细胞癌与良性结节
AJR Am J Roentgenol. 2011 Nov;197(5):W868-75. doi: 10.2214/AJR.10.6237.

引用本文的文献

1
Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma.经动脉化疗栓塞术(TACE)联合乐伐替尼与TACE联合索拉非尼治疗中晚期肝细胞癌的疗效及安全性比较
Am J Transl Res. 2023 Feb 15;15(2):1117-1128. eCollection 2023.

本文引用的文献

1
LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.钆塞酸增强 MRI 的 LI-RADS 治疗反应分类:与 mRECIST 的诊断性能比较及辅助特征的附加价值。
Eur Radiol. 2020 May;30(5):2861-2870. doi: 10.1007/s00330-019-06623-9. Epub 2020 Jan 31.
2
Potential of Gd-EOB-DTPA as an imaging biomarker for liver injury estimation after radiation therapy.钆塞酸二钠(Gd-EOB-DTPA)作为放射治疗后肝损伤评估的影像学生物标志物的潜力。
Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):354-359. doi: 10.1016/j.hbpd.2019.05.005. Epub 2019 May 20.
3
Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.
白蛋白-胆红素(ALBI)与 Child-Turcotte-Pugh(CTP)在立体定向体部放射治疗后 HCC 预后中的比较。
Radiat Oncol. 2019 Mar 27;14(1):50. doi: 10.1186/s13014-019-1251-y.
4
Radiation-Induced Liver Disease and Modern Radiotherapy.放射性肝损伤与现代放疗
Semin Radiat Oncol. 2018 Oct;28(4):321-331. doi: 10.1016/j.semradonc.2018.06.007.
5
Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).西方接受立体定向体部放射治疗(SBRT)的肝细胞癌患者的基线白蛋白-胆红素(ALBI)评分。
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):900-909. doi: 10.1016/j.ijrobp.2018.04.011. Epub 2018 Apr 12.
6
Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.立体定向体部放疗(SBRT)治疗肝转移瘤——RSSearch®国际多机构患者注册研究的临床结果。
Radiat Oncol. 2018 Feb 13;13(1):26. doi: 10.1186/s13014-018-0969-2.
7
Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment.肝细胞癌的立体定向体部放射治疗(SBRT):治疗后影像评估
Br J Radiol. 2018 May;91(1085):20170118. doi: 10.1259/bjr.20170118. Epub 2018 Feb 1.
8
Dose to organ at risk and dose prescription in liver SBRT.肝脏立体定向放射治疗中危及器官的剂量及剂量处方
Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):96-102. doi: 10.1016/j.rpor.2017.03.001. Epub 2017 Apr 17.
9
Radiation therapy for hepatobiliary malignancies.肝胆恶性肿瘤的放射治疗
J Gastrointest Oncol. 2017 Apr;8(2):279-292. doi: 10.21037/jgo.2016.08.02.
10
Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.评估白蛋白-胆红素(ALBI)分级作为经动脉放射性栓塞治疗的肝细胞癌患者的预后指标
Am J Clin Oncol. 2018 Sep;41(9):861-866. doi: 10.1097/COC.0000000000000384.